-
Genome-editing medicinal products: the EMA perspective Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2024-03-15
Discover the world’s best science and medicine | Nature.com
-
NASH field celebrates ‘hurrah moment’ with a first FDA drug approval for the liver disease Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2024-03-14
Madrigal’s resmetirom has scored a landmark FDA win, bolstering hopes for a diverse pipeline of drugs for non-alcoholic steatohepatitis.
-
Upcoming market catalysts in Q2 2024 Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2024-03-13
Discover the world’s best science and medicine | Nature.com
-
Engineered T cells call for back-up Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2024-03-12
Discover the world’s best science and medicine | Nature.com
-
The European Innovation Network as a hub for medicines innovation in Europe Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2024-03-11 Eleonora Agricola, Caroline Auriche-Benichou, Helena Baiao, Oriane Blanquie, Teodora Bodea, Tomáš Boráň, John-Joseph Borg, Valentina Cordo’, Maria Di Marzo, Lars Dmowski Rugholm, Falk Ehmann, Rúna Hauksdóttir Hvannberg, Ralf Herold, Alar Irs, Simona Jurkovič Mlakar, Robert Klaus, Juha Kolehmainen, Christophe Lahorte, Wiebke Löbker, Anna Mäkinen Salmi, Yoana Nuevo Ordoñez, Laurence O’Dwyer, Anna Maria
The European Innovation Network is working to support the European medical innovation ecosystem by facilitating early dialogue between developers of medicines and regulators, as well as providing a platform for regulators to share information, good practices and expertise.
-
Shifts in the clinical trial landscape Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2024-03-08
Discover the world’s best science and medicine | Nature.com
-
GSK’s first-in-class antibiotic secures another phase III win, approaches regulatory run Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2024-03-08
Discover the world’s best science and medicine | Nature.com
-
Ribosome-targeted antibiotic tackles antimicrobial resistance Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2024-03-06
Discover the world’s best science and medicine | Nature.com
-
Top companies and drugs by sales in 2023 Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2024-03-08
Discover the world’s best science and medicine | Nature.com
-
Suppressing tumour Treg cells with a histone demethylase inhibitor Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2024-03-07
Discover the world’s best science and medicine | Nature.com
-
Increasing the potency of T cell therapies Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2024-03-06
Discover the world’s best science and medicine | Nature.com
-
Targeting proteins with bivalent glues Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2024-03-06
Discover the world’s best science and medicine | Nature.com
-
Making macrophages with anti-tumour activity Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2024-03-06
Discover the world’s best science and medicine | Nature.com
-
MYC inhibitor achieves phase I success Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2024-03-06
Discover the world’s best science and medicine | Nature.com
-
The present and future of bispecific antibodies for cancer therapy Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2024-03-06 Christian Klein, Ulrich Brinkmann, Janice M. Reichert, Roland E. Kontermann
-
Monkeypox mRNA vaccine protects mice and macaques Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2024-03-04
Discover the world’s best science and medicine | Nature.com
-
From basic research to budding biotechs, under one roof with Stuart Schreiber Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2024-03-01
Stuart Schreiber discusses his plans to tackle inefficiencies in the translation of biomedical research, through the newly launched for-profit institute Arena BioWorks.
-
Therapeutic developments for tuberculosis and nontuberculous mycobacterial lung disease Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2024-02-28 Véronique Dartois, Thomas Dick
-
Opportunities and challenges for innovative and equitable healthcare Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2024-02-26 David J. Ecker, Clarice D. Aiello, Joseph R. Arron, C. Frank Bennett, Amy Bernard, Xandra O. Breakefield, Timothy J. Broderick, Shawneequa L. Callier, Barry Canton, Janice S. Chen, C. Simone Fishburn, Banning Garrett, Sidney M. Hecht, Tobias Janowitz, Melinda Kliegman, Adrian Krainer, Chrystal U. Louis, Christopher Lowe, Alfica Sehgal, Yesim Tozan, Kevin J. Tracey, Fyodor Urnov, Daniel Wattendorf,
An unprecedented number of potentially disruptive therapeutic technologies are under development. Forward-looking policies, incentives and infrastructure are needed to harness these advances to provide effective and globally equitable healthcare.
-
FDA approves first tumour-infiltrating lymphocyte (TIL) therapy, bolstering hopes for cell therapies in solid cancers Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2024-02-19
Discover the world’s best science and medicine | Nature.com
-
When can AI deliver the drug discovery hits? Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2024-02-19
The CACHE hit-finding competition highlights the potential of AI to identify small molecules that bind to hard-to-drug targets — and the long road ahead for these computational screening approaches.
-
Approvals by the China NMPA in 2023 Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2024-02-19
Discover the world’s best science and medicine | Nature.com
-
New NIH director’s research agenda spans “the laboratory, the clinic and the community” Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2024-02-19
Monica Bertagnolli, the newly appointed director of the NIH, discusses diversity, inclusion and access to biomedical research.
-
Vertex’s non-opioid painkiller passes phase III tests Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2024-02-12
Discover the world’s best science and medicine | Nature.com
-
Sanofi buys Inhibrx and drug for alpha-1 antitrypsin deficiency for US$1.7 billion Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2024-02-12
Discover the world’s best science and medicine | Nature.com
-
BMP9 stands up to sepsis Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2024-02-12
Discover the world’s best science and medicine | Nature.com
-
Novartis bets US$2.9 billion on MorphoSys and an anti-myelofibrosis drug Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2024-02-12
Discover the world’s best science and medicine | Nature.com
-
BTK degraders tackle drug resistance Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2024-02-09
Discover the world’s best science and medicine | Nature.com
-
The colorectal cancer drug market Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2024-02-09
Discover the world’s best science and medicine | Nature.com
-
SLC15A4 inhibitor blocks inflammation Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2024-02-07
Discover the world’s best science and medicine | Nature.com
-
i-shaped antibodies achieve receptor agonism Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2024-02-07
Discover the world’s best science and medicine | Nature.com
-
Improving liquid biopsy for cancer detection Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2024-02-07
Discover the world’s best science and medicine | Nature.com
-
Brain glucose mediates amphotericin B tolerance Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2024-02-07
Discover the world’s best science and medicine | Nature.com
-
The Bespoke Gene Therapy Consortium: facilitating development of AAV gene therapies for rare diseases Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2024-02-06 P. J. Brooks, Timothy M. Miller, Frédéric Revah, Junghae Suh, Bradley R. Garrison, Lawrence C. Starke, Timothy K. MacLachlan, Edward G. Neilan, Gopa Raychaudhuri, Sadik H. Kassim, Jean Dehdashti, Joni L. Rutter
A public–private consortium established by the FNIH aims to address biological, manufacturing and regulatory challenges to the development of gene therapies for rare diseases.
-
Macrocyclic peptides thwart Gram-negative bacteria Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2024-02-05
Discover the world’s best science and medicine | Nature.com
-
Bispecific antibody boosts dendritic cell–T cell crosstalk Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2024-01-31
Discover the world’s best science and medicine | Nature.com
-
The pipeline and market for psoriasis drugs Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2024-01-31
Discover the world’s best science and medicine | Nature.com
-
Open science in precision medicine for neurodegenerative diseases Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2024-01-29 Hampton L. Leonard, Mike A. Nalls, Aaron Day-Williams, Sahar Esmaeeli, Paige Jarreau, Sara Bandres-Ciga, Peter Heutink, Pablo Sardi, Andrew B. Singleton
Open science initiatives that harness human genomic and genetic data could help increase the likelihood of successfully developing new drugs for neurodegenerative diseases.
-
Membrane transporters in drug development and as determinants of precision medicine Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2024-01-24 Aleksandra Galetin, Kim L. R. Brouwer, Donald Tweedie, Kenta Yoshida, Noora Sjöstedt, Lauren Aleksunes, Xiaoyan Chu, Raymond Evers, Michael J. Hafey, Yurong Lai, Pär Matsson, Andrew Riselli, Hong Shen, Alex Sparreboom, Manthena V. S. Varma, Jia Yang, Xinning Yang, Sook Wah Yee, Maciej J. Zamek-Gliszczynski, Lei Zhang, Kathleen M. Giacomini
-
Strategies to reduce the risks of mRNA drug and vaccine toxicity Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2024-01-23 Dimitrios Bitounis, Eric Jacquinet, Maximillian A. Rogers, Mansoor M. Amiji
-
Biopharma dealmaking in 2023 Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2024-01-16
Discover the world’s best science and medicine | Nature.com
-
2023 FDA approvals: unprecedented volume at moderate value Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2024-01-17
Discover the world’s best science and medicine | Nature.com
-
Muscarinic receptor modulators for schizophrenia attract multibillion-dollar attention Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2024-01-15
Discover the world’s best science and medicine | Nature.com
-
Radiopharmaceuticals garner continued M&A investments Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2024-01-15
Discover the world’s best science and medicine | Nature.com
-
Biopharma M&A flow picks up Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2024-01-15
Discover the world’s best science and medicine | Nature.com
-
Circular RNA vaccines expose cryptic peptides Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2024-01-15
Discover the world’s best science and medicine | Nature.com
-
Stalled molecular motor inhibits tumour growth Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2024-01-12
Discover the world’s best science and medicine | Nature.com
-
Monoclonal antibody to treat fentanyl overdose Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2024-01-12
Discover the world’s best science and medicine | Nature.com
-
High-throughput profiling of reactive cysteines Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2024-01-12
Discover the world’s best science and medicine | Nature.com
-
Explainable deep learning discovers novel antibiotic Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2024-01-12
Discover the world’s best science and medicine | Nature.com
-
Eliminating IgE reverses allergy Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2024-01-12
Discover the world’s best science and medicine | Nature.com
-
Modified mRNA produces frameshifted peptides Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2024-01-10
Discover the world’s best science and medicine | Nature.com
-
Targeting glial lipid metabolism to tackle neurodegeneration Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2024-01-10
Discover the world’s best science and medicine | Nature.com
-
Disproportional inflation of clinical trial costs: why we should care, and what we should do about it Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2024-01-09 Hemme J. Hijma, Ahnjili Zhuparris, Ewoud-Jan van Hoogdalem, Adam F. Cohen
Clinical trial costs seem to be inflating excessively, without a clear increase in the value of the information gained. Here, we highlight factors that could be driving this trend and discuss potential solutions.
-
2023 FDA approvals Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2024-01-02
The FDA approved 55 novel therapeutics in 2023, the second highest count in the past 30 years.
-
Targeting hypoxia-inducible factors: therapeutic opportunities and challenges Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-12-20 Xiaoyi Yuan, Wei Ruan, Bentley Bobrow, Peter Carmeliet, Holger K. Eltzschig
-
Drug targeting in psychiatric disorders — how to overcome the loss in translation? Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-12-19 Konstantin Khodosevich, Katarina Dragicevic, Oliver Howes
-
The landscape and market for HIV therapies Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-12-15
Discover the world’s best science and medicine | Nature.com
-
Therapeutic targeting of the functionally elusive TAM receptor family Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-12-13 Yu Rebecca Miao, Erinn B. Rankin, Amato J. Giaccia
-
Tumour-infiltrating lymphocyte cancer therapy nears FDA finish line Nat. Rev. Drug. Disc. (IF 120.1) Pub Date : 2023-12-13
The FDA could soon approve Iovance’s lifileucel for advanced melanoma, a much-anticipated milestone for the 35-year-old T cell therapy modality.